---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051852"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2026-08-03T20:14:27+00:00"
generated_at: "2026-08-03T20:16:21.796379+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q2 revenue $114.4M, exome/genome volume up 32% YoY; reiterates FY guidance

## Summary
- Q2 revenue $114.4M (+11% YoY); exome/genome revenue $100.3M (+17% YoY).
- Exome/genome volume 30,785 (+32% YoY); adjusted gross margin 70% (GAAP 68%).
- Adjusted net income $0.4M (up $8.6M from Q1); GAAP net loss $17.7M.
- Reiterates FY2026 revenue guidance $475-490M with exome/genome volume growth at least 30%.
- Amended Blackstone loan: additional $50M term loan (total $150M); Blackstone bought $5M stock at $61/share; pro forma cash ~$188M.

## SEC filing metadata
- accession: 0001628280-26-051852
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2026-08-03T20:14:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/0001628280-26-051852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/wgs-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051852
- JSON: https://secwatch.observer/filing/0001628280-26-051852.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.